


Peplomycin

Cat. No.:	HY-106364
CAS No.:	68247-85-8
Molecular Formula:	C ₆₁ H ₈₈ N ₁₈ O ₂₁ S ₂
Molecular Weight:	1473.59
Target:	Antibiotic
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Peplomycin (Bleomycin PEP; Pepleomycin) is an antibiotic analogue of Bleomycin (HY-108345), with high antitumor effect and less pulmonary toxicity. Peplomycin induce apoptosis in oral squamous carcinoma cell line SSKN cells and pulmonary fibrosis in rats ^{[1][2][3][4]} .								
In Vitro	<p>Peplomycin (0-100 μM; 30 h) inhibits human oral squamous carcinoma cell line SSKN and SCCTF cells in a dose-dependent manner^[3].</p> <p>Peplomycin (1 μM and 10 μM; 30 h) results nuclear fragmentation and condensation of chromatin in cells dose-dependently and induces apoptosis^[3].</p> <p>Peplomycin (5 mg/mL; 7 d) induces pulmonary fibrosis separated from saline-injected rats (N-Fib) by differentiating fibroblasts to alpha-SMA-positive MF^[4].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[3]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>SSKN and SCCTF cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 1, 5, 10, 50, and 100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>30 hours</td> </tr> <tr> <td>Result:</td> <td>Decreased SSKN and SCCTF cells viability dose-dependently up to 50 μM, and resulted the viability of 38% and 30% that of the control group, respectively.</td> </tr> </table>	Cell Line:	SSKN and SCCTF cells	Concentration:	0, 1, 5, 10, 50, and 100 μM	Incubation Time:	30 hours	Result:	Decreased SSKN and SCCTF cells viability dose-dependently up to 50 μM, and resulted the viability of 38% and 30% that of the control group, respectively.
Cell Line:	SSKN and SCCTF cells								
Concentration:	0, 1, 5, 10, 50, and 100 μM								
Incubation Time:	30 hours								
Result:	Decreased SSKN and SCCTF cells viability dose-dependently up to 50 μM, and resulted the viability of 38% and 30% that of the control group, respectively.								
In Vivo	<p>Peplomycin (5 mg/kg; once daily) induces rat pulmonary fibroblasts to myofibroblasts (MF), while the peripheries of lungs adjacent to the pleura reveals advanced fibrosis with a small number of alpha-smooth muscle actin (alpha-SMA)-positive MF, which ultrastructurally possessed abundant microfilaments and cellular organelles^[4].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								

REFERENCES

- [1]. Carter SK, et al. Peplomycin. *Cancer Treat Rev.* 1984 Dec;11(4):303-5.
- [2]. Asano Y, et al. A case of peplomycin-induced scleroderma. *Br J Dermatol.* 2004 Jun;150(6):1213-4.

[3]. Okamura H, et al. Peplomycin-induced apoptosis in oral squamous carcinoma cells depends on bleomycin sensitivity. *Oral Oncol.* 2001 Jun;37(4):379-85.

[4]. Osaki T, et al. Peplomycin, a bleomycin derivative, induces myofibroblasts in pulmonary fibrosis. *Int J Exp Pathol.* 2001 Aug;82(4):231-41.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA